GlassScriptPhysician profile
Kaitlyn Doll
NPI 1366205601
$1,664.34
in general payments reported to CMS, 2019-2025
23 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $524 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.34 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $578.55 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $213.61 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $136.05 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $97.38 | 2025 | |
| Dexcom, INC. | $74.81 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $60.30 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $51.71 | 2025 | |
| Stryker Corporation | $49.33 | 2025 | Mako |
| Sanofi-Aventis U.S. LLC | $40.50 | 2024-2025 | |
| Corcept Therapeutics | $40.24 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.92 | 2024-2025 | Jardiance |
| Medtronic, INC. | $33.98 | 2025 | Intellis Adaptivestim, Venaseal |
| Lilly USA, LLC | $32.59 | 2025 | Jardiance, Zepbound, Mounjaro |
| Beta Bionics, INC. | $31.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astrazeneca Pharmaceuticals LP | $28.85 | 2024-2025 | Airsupra, Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.59 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $19.74 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Pfizer INC. | $19.41 | 2024 | |
| Antares Pharma, INC. | $19.00 | 2025 | Xyosted |
| Recordati_rare_diseases_inc. | $17.39 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $15.58 | 2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $14.08 | 2025 | Licart, Flector, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Doll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.